SCHEMBL4043422

SCHEMBL4043422

CC(=O)CCN(CCNc1ccc(Cl)c(Cl)c1C(N)=O)C(=O)OC(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 1/20 0.32
AAK1 Q2M2I8 1/20 0.32
LIN28A Q9H9Z2 1/20 0.31
CDC7 O00311 1/20 0.31
PLK4 O00444 1/20 0.31
DYRK3 O43781 1/20 0.31
JAK2 O60674 1/20 0.31
ROCK2 O75116 1/20 0.31
PRKD3 O94806 1/20 0.31
MAP4K4 O95819 1/20 0.31
INSR P06213 1/20 0.31
CDK1 P06493 1/20 0.31
ROS1 P08922 1/20 0.31
PIM1 P11309 1/20 0.31
FGFR1 P11362 1/20 0.31
PRKACA P17612 1/20 0.31
FLT1 P17948 1/20 0.31
RPS6KB1 P23443 1/20 0.31
CDK2 P24941 1/20 0.31
EPHA2 P29317 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5288545 0.84 AAK1 (0.32) AAK1CSF1R
SCHEMBL4043430 0.74
SCHEMBL5288536 0.73 DRD2 (0.32) CDC7PLK4DYRK3JAK2ROCK2
SCHEMBL8730869 0.66 CDC7 (0.37) LIN28ACDC7PLK4DYRK3JAK2
SCHEMBL4049896 0.66 CXCR2 (0.39) LIN28ACDC7PLK4DYRK3JAK2
SCHEMBL3975488 0.65 CA14 (0.42) CA14
SCHEMBL8735080 0.64 CDC7 (0.37) LIN28ACDC7PLK4DYRK3JAK2
SCHEMBL17149486 0.63 CA14 (0.40) CA14
SCHEMBL21865673 0.63 AHCY (0.40)
SCHEMBL23900953 0.63 CA14 (0.41) CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846410-B1 DIHYDROQUINAZOLINONES AS 5HT MODULATORS BRISTOL MYERS SQUIBB CO (US) 2009-01-21 EP disclosed
EP-1846410-A2 DIHYDROQUINAZOLINONES AS 5HT MODULATORS Bristol-Myers Squibb Company (US) 2007-10-24 EP disclosed
US-7238702-B2 Dihydroquinazolinones as 5HT modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-03 US disclosed
WO-2006086464-A2 DIHYDROQUINAZOLINONES AS 5HT MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-17 WO disclosed
US-20060178386-A1 Dihydroquinazolinones as 5HT modulators BRISTOL-MYERS SQUIBB COMPANY 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178386-A1 Dihydroquinazolinones as 5HT modulators HTR3B, HTR2C, HTR2B CA14 4604/4885AAK1 1287/4885LIN28A 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.